The breast lesion localization market is estimated to reach USD 877.9 Million by 2020 from USD 445.9 Million in 2015, at a CAGR of 14.5% from 2015 to 2020.
The overall market for breast lesion localization methods is expected to witness rapid growth owing to the increasing number of breast cancer surgeries and implementation of favorable reimbursement guidelines. Furthermore, the rising demand for better quality care, and growing awareness amongst patients about breast cancer screening are the other major factors driving the breast lesion localization methods market. On the other hand, market growth will be restrained by the uncertainty in regulatory approval procedures as a result of the risks associated with breast lesion localization devices. However, force field analysis of the market depicts that the driving forces outweigh the restraining forces.
Based on the type of localization devices, the market is segmented into wire localization, radioisotope localization (radioactive seed localization, radio occult lesion localization), magnetic tracers, and others. Among these segments, wire localization is the major focus of players as it is an established technique in the market. Also, the comparative analysis of four major types of localization methods shows that wire localization is still the gold standard for breast localization, resulting in continued adoption of this technique among end users. However, according to the replacement trends studied in all geographies, most end users are expected to switch from wire localization to radio-guided localization methods (especially radioactive seed localization) in the near future.
This report contains detailed analysis of end user preferences for the adoption of different breast lesion localization methods. The research findings cited in the report encapsulate the important selection criteria for breast lesion localization methods from an end-user perspective. It analysis the importance given to a particular criteria by end users during the selection of a breast lesion localization method; some of the important selection criteria include detection and success rate, re-excision rate, cost, mean localization time, effectiveness, safety, ease of use, and mean operating time.
About MarketsandMarkets™ MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including: